Lais P. Ghiraldeli is a law clerk in Sterne Kessler’s Biotechnology & Chemical Practice Group, where she assists in the preparation and prosecution of U.S. and foreign patent applications and assists with patentability, validity, infringement, and freedom-to-operate analyses. Her areas of technical expertise includes organic chemistry, cancer biology, biochemistry, integrative physiology, pharmacology, CRISPR technology, and applied mathematics.

Lais is a law student at the University of New Hampshire Franklin Pierce School of Law. She received her M.S. in integrative physiology and pharmacology with an emphasis on cancer biology from Wake Forest University, where her graduate research and thesis focused on the role of Adenosine Monophosphate Activated Protein Kinases (AMPK) in chemotherapeutic response in Acute Myeloid Leukemia. In addition, Lais researched the stimulation of the Blood Brain Barrier (BBB) during drug transport with Locked Nucleic Acid (LNA) conjugates by targeting adenosine receptors (A2A) in glioblastoma. Lais received her B.S. in Chemistry, with a Mathematics minor, from Seton Hall University. As an undergraduate, her research focused on the structural determinants of oncogene overexpression in Acute Lymphoblastic Leukemia and the mathematical matrices between the energy levels of unsaturated hydrocarbons.

Technical Publications

  • First-author, Adenosine Monophosphate Activated Protein Kinase (AMPK) enhances chemotherapy response in Acute Myeloid Leukemia (AML), CANCER LETTERS, June 1, 2022.
  • Co-author, Improved anti-Tumor Activity of the Fluoropyrimidine Polymer CF10 in pre-Clinical Colorectal Cancer Models thru Distinct Mechanistic and Pharmacological Properties, MOLECULAR CANCER THERAPEUTICS, December 23, 2020.
  • Co-author, Mitochondria in Cancer Metabolism, an organelle whose time has come?, BBA-REVIEWS ON CANCER, May 26, 2018.
  • Co-author, A phase I study of CPI-613 in combination with high dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia, CLINICAL CANCER RESEARCH, February 6, 2018.

  • B.S., (Candidate 2026), Seton Hall University
  • B.S., Integrative Physiology and Pharmacology / Cancer Biology, Seton Hall University
  • B.S., Chemistry (Mathematics minor), Seton Hall University, cum laude

  • Portuguese
  • Spanish
  • Italian